SEC Form 4 · accession 0001209191-17-041664
Arbutus Biopharma Corp · ABUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keith S Manchester
Director
Period of report
Jun 21, 2017
Accepted (ET)
Jun 23, 2017 · 4:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001447028
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2,F1 | $3.55 | Jun 21, 2017 | A | 22,000 | A | — | Jun 21, 2027 | Common Stock | 22,000 | 22,000 | D |
Explanation of responses
- F1The shares underlying this option fully vested on June 21, 2017.
- F2Dr. Manchester is the Head of Life Sciences and a Portfolio Manager at QVT Financial LP and serves as a director on behalf of QVT Financial LP and its affiliates. Dr. Manchester holds these stock options for the benefit of certain funds managed by QVT Financial LP.